Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Table 2 Tumor response according to RECIST version 1.1 in the two groups
| Group | n | PR | SD | PD | ORR | DCR |
| Control group | 92 | 22 (23.91) | 42 (45.65) | 28 (30.43) | 22 (23.91) | 64 (69.57) |
| Experimental group | 31 | 10 (32.26) | 13 (41.94) | 8 (25.81) | 10 (32.26) | 23 (74.19) |
| P value | 0.650 | 0.356 | 0.835 | 0.820 | 0.356 | 0.820 |
- Citation: Zhang C, Wu SH, Jin L, Lu L, Li J, Jin S. Propensity score-based real-world study of immune checkpoint inhibitor combination therapy in microsatellite stable/proficient mismatch repair metastatic colorectal cancer. World J Gastrointest Oncol 2026; 18(11): 124022
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/124022.htm
- DOI: https://dx.doi.org/10.4251/wjgo.124022